Search Within

Geoffrey Yuyat Ku

  1. "Jinru Shia"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (7)
  2. Department of Pathology and Laboratory Medicine (7)
  3. Gastrointestinal Oncology Service (7)
  4. Hematologic Malignancies, Division of (7)
  5. Solid Tumor Oncology Division (7)
  6. Center for Pancreatic Cancer Research (5)

More Groups

People
  1. Jinru Shia (7)
  2. Yelena Janjigian (6)
  3. David Ilson (4)
  4. Laura Tang (4)
  5. Avni Desai (3)
  6. David Solit (3)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (1)
Publications
  1. Annals of Oncology (1)
  2. Cancer Discovery (1)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Journal of Clinical Oncology (1)
  5. Journal of Gastrointestinal Oncology (1)
  6. Lancet Oncology (1)

More Publications

Publishers
  1. Oxford University Press (2)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Science, Inc. (1)
  5. Massachusetts Medical Society (1)
  6. Pioneer Bioscience Publishing Company (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nonoperative management of mismatch repair-deficient tumors
    Journal Article

    Cercek, A.; Foote, M. B.; Rousseau, B.; Smith, J. J.; Shia, J.; Sinopoli, J.; Weiss, J.; Lumish, M.; Temple, L.; Patel, M.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • ATM germline-mutated gastroesophageal junction adenocarcinomas: Clinical descriptors, molecular characteristics, and potential therapeutic implications
    Journal Article

    El Jabbour, T.; Misyura, M.; Cowzer, D.; Zimmermann, M.; Rimkunas, V.; Marra, A.; Derakhshan, F.; Selenica, P.; Parilla, M.; Setton, J. S.; more...
    JNCI: Journal of the National Cancer Institute (2022)

    Fulltext@MSK | Save
  • Maximizing response: A case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma
    Journal Article

    Greally, M.; Agarwal, R.; El Dika, I.; Shamseddine, A.; El-Olayan, A.; Haibe, Y.; Paroder, V.; Shia, J.; Abou-Alfa, G. K.; Ku, G. Y.
    Journal of Gastrointestinal Oncology (2019)

    Fulltext@MSK | Save
  • Genetic predictors of response to systemic therapy in esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Chatila, W. K.; Hechtman, J. F.; Ku, G. Y.; Riches, J. C.; Tuvy, Y.; Kundra, R.; Bouvier, N.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients
    Meeting Abstract

    Ku, G. Y.; Sanchez-Vega, F.; Chatila, W.; Margolis, M.; Fein, C.; Ilson, D. H.; Hechtman, J. F.; Tuvy, Y.; Bouvier, N.; Kundra, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save